Nijmegen, The Netherlands and Gothenburg, Sweden, May 31, 2011 - Synthon and MIVAC Development announced today that they have entered into a new, exclusive and broad ranging research and development collaboration to produce innovative treatments for patients with multiple sclerosis.
The collaboration will combine Synthon’s expertise in the pharmaceutical arena and business acumen with MIVAC Development’s tolerance-inducing fusion protein technology.
Under the collaboration, Synthon and MIVAC Development will create multiple new therapeutic candidates, research and screen these to identify novel lead compounds which Synthon will develop further into the clinic and bring onto the market.
The result of this collaboration could be a new treatment paradigm for multiple sclerosis patients offering superior efficacy with greater ease of use and improved tolerability.
Synthon is an international pharmaceutical company which develops, manufactures and out-licenses specialty pharmaceutical products. Employing more than 1300 staff worldwide, Synthon is headquartered in the Netherlands and has subsidiaries in ten other countries. The company has strong expertise in R&D, IP and Regulatory Affairs and produces the active pharmaceutical ingredients of its medicines as well as the finished product. Synthon offers a wide portfolio of generic products, which are made available worldwide through local marketing partners. Synthon has started research and development in the biopharmaceutical area, which will result in a new generation of medicines. Multiple sclerosis is one of Synthon’s therapeutic area focuses and the company has built up significant competence in the field. www.synthon.com
About MIVAC Development
MIVAC Development, located in the Biotech Center Gothenburg, Sweden, is a Biopharmaceutical Company focused on discovery, development and commercialization of novel treatments of autoimmune diseases, tolerance inducing therapies, and mucosal vaccines. MIVAC Development´s project pipeline includes e.g. an antibody for Alzheimer’s disease, tolerance treatment for Rheumatoid arthritis and vaccine for Helicobacter pylori infection. The company has a proprietary tolerance-inducing fusion protein platform technology, which has utility in several disease areas.
For more information:
Senior Manager Corporate Communications Synthon
+31 24 372 7759 / +31 5125 3916
CEO MIVAC Development AB
+46 706 31 00 34
MIVAC Developments affärsidé är att driva nya idéer och resultat från forskning via preklinisk utveckling till klinisk prövning och kommersialisering i samarbete med finansiärer och industripartners och att avyttra eller avknoppa dem vid lämpligt tillfälle.